SecBot SecBot

Interagency Patent Coordination and Improvement Act of 2023

H.R. 1717 Rep. Joe Neguse (D-CO-2) In committee
  1. Introduced Mar 22
  2. Committee Mar 22
  3. Passed House Next
  4. Passed Senate Not yet
  5. To President Not yet
  6. Law Not yet
Where it stands
In committee, Mar 22, 2023Next: House vote
1316d ago Mar 22, 2023: Referred to the House Committee on the Judiciary.
Final votes
No roll callsNo recorded vote on this bill yet
Lobbying
6companies, 7 filings
Member trades
14trades in the last 90 days
Who backs the bill and who pushes back Subscribe

Companies lobbying on this bill

6 companies
Companies by sector
Biotech & Pharma 6
Search all 6 companies, their asks and price moves Subscribe

Summary

Interagency Patent Coordination and Improvement Act of 2023

Full summary2 paragraphs

This bill establishes the Interagency Task Force on Patents to support coordination and communication between the U.S. Patent and Trademark Office (PTO) and the Food and Drug Administration (FDA) on activities relating to patents for human drugs and biological products.

The task force's duties shall include sharing information about (1) the processes of each agency, including how each agency evaluates applications (e.g., patent applications at the PTO and new drug applications at the FDA); and (2) new approvals of patents, human drugs, biological products, and new technologies. The task force must also establish a process that requires (1) the PTO to request from the FDA information relating to certain patent applications to help patent examiners carry out their duties, (2) the FDA to provide such information to the PTO, and (3) the PTO to assist the FDA in its ministerial role of listing patents.

Library of Congress summary, Mar 22, 2023

Summary versions
  • Introduced in HouseMar 22, 2023

Official record from Congress.gov, the House Clerk and the Senate; lobbying from Lobbying Disclosure Act filings. Updated Oct 27, 2026.